Two distinct effector memory cell populations of WT1 (Wilms’ tumor gene 1)-specific cytotoxic T lymphocytes in acute myeloid leukemia patients

Wilms’ tumor gene 1 (WT1) protein is a promising tumor-associated antigen for cancer immunotherapy. We have been performing WT1 peptide vaccination with good clinical responses in over 750 patients with leukemia or solid cancers. In this study, we generated single-cell gene-expression profiles of the effector memory (EM) subset of WT1-specific cytotoxic T lymphocytes (CTLs) in peripheral blood of nine acute myeloid leukemia patients treated with WT1 peptide vaccine, in order to discriminate responders (WT1 mRNA levels in peripheral blood decreased to undetectable levels, decreased but stayed at abnormal levels, were stable at undetectable levels, or remained unchanged from the initial abnormal levels more than 6 months after WT1 vaccination) from non-responders (leukemic blast cells and/or WT1 mRNA levels increased relative to the initial state within 6 months of WT1 vaccination) prior to WT1 vaccination. Cluster and principal component analyses performed using 83 genes did not discriminate between responders and non-responders prior to WT1 vaccination. However, these analyses revealed that EM subset of WT1-specific CTLs could be divided into two groups: the “activated” and “quiescent” states; in responders, EM subset of the CTLs shifted to the “quiescent” state, whereas in non-responders, those shifted to the “activated” state following WT1 vaccination. These results demonstrate for the first time the existence of two distinct EM states, each of which was characteristic of responders or non-responders, of WT1-specific CTLs in AML patients, and raises the possibility of using advanced gene-expression profile analysis to clearly discriminate between responders and non-responders prior to WT1 vaccination.

[1]  J. Hatazawa,et al.  Phase II clinical trial of Wilms tumor 1 peptide vaccination for patients with recurrent glioblastoma multiforme. , 2008, Journal of neurosurgery.

[2]  Marius Wernig,et al.  Comprehensive qPCR profiling of gene expression in single neuronal cells , 2011, Nature Protocols.

[3]  N. Weng,et al.  The molecular basis of the memory T cell response: differential gene expression and its epigenetic regulation , 2012, Nature Reviews Immunology.

[4]  Y. Oka,et al.  WT1 peptide immunotherapy for cancer in children and young adults , 2010, Pediatric blood & cancer.

[5]  J. Hatazawa,et al.  A phase I/II trial of a WT1 (Wilms' tumor gene) peptide vaccine in patients with solid malignancy: safety assessment based on the phase I data. , 2006, Japanese journal of clinical oncology.

[6]  J. Sakamoto,et al.  WT1 peptide vaccine induces reduction in minimal residual disease in an Imatinib‐treated CML patient , 2010, European journal of haematology.

[7]  K. Aozasa,et al.  WT1 (WILMS TUMOR 1) PEPTIDE IMMUNOTHERAPY FOR CHILDHOOD RHABDOMYOSARCOMA: A Case Report , 2009, Pediatric hematology and oncology.

[8]  I. Kawase,et al.  WT1 Peptide‐Based Immunotherapy for Patients with Lung Cancer: Report of Two Cases , 2004, Microbiology and immunology.

[9]  H. Goossens,et al.  Induction of complete and molecular remissions in acute myeloid leukemia by Wilms’ tumor 1 antigen-targeted dendritic cell vaccination , 2010, Proceedings of the National Academy of Sciences.

[10]  M. Takiguchi,et al.  Differentiation of Human CD8+ T Cells from a Memory to Memory/Effector Phenotype1 , 2002, The Journal of Immunology.

[11]  Veronica Sanchez-Freire,et al.  Microfluidic single-cell real-time PCR for comparative analysis of gene expression patterns , 2012, Nature Protocols.

[12]  J. Wolchok,et al.  Vaccination with synthetic analog peptides derived from WT1 oncoprotein induces T-cell responses in patients with complete remission from acute myeloid leukemia. , 2010, Blood.

[13]  T. Kyo,et al.  Induction of WT1 (Wilms' tumor gene)-specific cytotoxic T lymphocytes by WT1 peptide vaccine and the resultant cancer regression. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[14]  Quin F. Wills,et al.  Methods for qPCR gene expression profiling applied to 1440 lymphoblastoid single cells , 2013, Methods.

[15]  D. Housman,et al.  An internal deletion within an 11p13 zinc finger gene contributes to the development of Wilms' tumor , 1990, Cell.

[16]  H. Sugiyama,et al.  Wilm's tumor gene WT1 peptide immunotherapy for pulmonary metastasis from adenoid cystic carcinoma of the salivary gland. , 2011, Oral oncology.

[17]  S M Hewitt,et al.  Regulation of the proto-oncogenes bcl-2 and c-myc by the Wilms' tumor suppressor gene WT1. , 1995, Cancer research.

[18]  D. Busch,et al.  The smallest unit: effector and memory CD8+ T cell differentiation on the single cell level , 2013, Front. Immun..

[19]  T. Yoshimine,et al.  Effects of concomitant temozolomide and radiation therapies on WT1-specific T-cells in malignant glioma. , 2010, Japanese journal of clinical oncology.

[20]  I. Kawase,et al.  WT1 peptide vaccine for the treatment of cancer. , 2008, Current opinion in immunology.

[21]  Anders Ståhlberg,et al.  Single-cell gene expression profiling using reverse transcription quantitative real-time PCR. , 2010, Methods.

[22]  J. Sakamoto,et al.  WT1 peptide immunotherapy for gynecologic malignancies resistant to conventional therapies: a phase II trial , 2013, Journal of Cancer Research and Clinical Oncology.

[23]  Lokesh P. Tripathi,et al.  TargetMine, an Integrated Data Warehouse for Candidate Gene Prioritisation and Target Discovery , 2011, PloS one.

[24]  Y. Oji,et al.  Vaccination with WT-1 (Wilms' tumor gene-1) peptide and BCG-CWS in melanoma. , 2012, European journal of dermatology : EJD.

[25]  I. Kawase,et al.  Wilms tumor gene peptide-based immunotherapy for patients with overt Leukemia from myelodysplastic syndrome (MDS) or MDS with myelofibrosis , 2003, International journal of hematology.

[26]  Thomas P. Loughran,et al.  HTLV-2 Tax Immortalizes Human CD4+ Memory T Lymphocytes by Oncogenic Activation and Dysregulation of Autophagy* , 2012, The Journal of Biological Chemistry.

[27]  J. Pelletier,et al.  The Wilms’ Tumor Suppressor Gene (wt1) Product Regulates Dax-1 Gene Expression during Gonadal Differentiation , 1999, Molecular and Cellular Biology.

[28]  H. Inohara,et al.  WT1 peptide therapy for a patient with chemotherapy-resistant salivary gland cancer. , 2012, Anticancer research.

[29]  P. Moss,et al.  Memory T Cells Constitute a Subset of the Human CD8+CD45RA+ Pool with Distinct Phenotypic and Migratory Characteristics1 , 2001, The Journal of Immunology.

[30]  A. Poustka,et al.  Homozygous deletion in Wilms tumours of a zinc-finger gene identified by chromosome jumping , 1990, Nature.

[31]  H. Harigae,et al.  Autophagy plays a protective role as an anti‐oxidant system in human T cells and represents a novel strategy for induction of T‐cell apoptosis , 2014, European journal of immunology.

[32]  J. Sakamoto,et al.  Clinical and immunologic responses to very low-dose vaccination with WT1 peptide (5 microg/body) in a patient with chronic myelomonocytic leukemia. , 2007, International journal of hematology.

[33]  H. Sugiyama.  Wilms’ Tumor GeneWT1: Its Oncogenic Function and Clinical Application , 2001, International journal of hematology.

[34]  T. Yoshimine,et al.  Prognostic value of WT1 protein expression level and MIB-1 staining index as predictor of response to WT1 immunotherapy in glioblastoma patients , 2010, Brain Tumor Pathology.

[35]  Martin A. Cheever,et al.  The Prioritization of Cancer Antigens: A National Cancer Institute Pilot Project for the Acceleration of Translational Research , 2009, Clinical Cancer Research.

[36]  N. Hosen,et al.  WT1 peptide vaccination following allogeneic stem cell transplantation in pediatric leukemic patients with high risk for relapse: successful maintenance of durable remission , 2012, Leukemia.

[37]  I. Kawase,et al.  Immunohistochemical detection of WT1 protein in a variety of cancer cells , 2006, Modern Pathology.

[38]  G. Soma,et al.  WT1 peptide vaccine stabilized intractable ovarian cancer patient for one year: a case report. , 2011, Anticancer research.

[39]  H. Sugiyama.  WT1 (Wilms' tumor gene 1): biology and cancer immunotherapy. , 2010, Japanese journal of clinical oncology.

[40]  T. Kyo,et al.  Long-term WT1 peptide vaccination for patients with acute myeloid leukemia with minimal residual disease , 2012, Leukemia.

[41]  Y. Aizawa,et al.  WT1 PEPTIDE VACCINATION IN COMBINATION WITH IMATINIB THERAPY FOR A PATIENT WITH CML IN THE CHRONIC PHASE , 2010, International journal of medical sciences.

[42]  T. Yoshimine,et al.  [Immunotherapy targeting the Wilms' tumor 1 gene product for patients with malignant brain tumors]. , 2009, Brain and nerve = Shinkei kenkyu no shinpo.

[43]  Y. Takeda,et al.  Wilms Tumor Gene (WT1) Peptide–based Cancer Vaccine Combined With Gemcitabine for Patients With Advanced Pancreatic Cancer , 2014, Journal of immunotherapy.

[44]  S. Kyo,et al.  Immunohistochemical detection of WT1 protein in endometrial cancer. , 2009, Anticancer research.

[45]  A. Sharov,et al.  Totipotent Embryonic Stem Cells Arise in Ground-State Culture Conditions , 2013, Cell reports.

[46]  J. Sakamoto,et al.  Wilms Tumor gene WT1 peptide-based immunotherapy induced a minimal response in a patient with advanced therapy-resistant multiple myeloma , 2007 .

[47]  C. Hess,et al.  Rapid effector function of memory CD8+ T cells requires an immediate-early glycolytic switch , 2013, Nature Immunology.

[48]  D. Green,et al.  Metabolic checkpoints in activated T cells , 2012, Nature Immunology.

[49]  Z. Berneman,et al.  Active specific immunotherapy targeting the Wilms' tumor protein 1 (WT1) for patients with hematological malignancies and solid tumors: lessons from early clinical trials. , 2012, The oncologist.

[50]  G I Bell,et al.  Repression of the insulin-like growth factor II gene by the Wilms tumor suppressor WT1. , 1992, Science.

[51]  J. Sakamoto,et al.  Wilms' tumor 1 (WT1) peptide immunotherapy for gynecological malignancy. , 2009, Anticancer research.